Associations - HER-2 amplification

HER-2 amplification	Non Small Cell Lung Cancer	HER-2 amplification	Non Small Cell Lung Cancer	disitamab vedotin Sensitive: C3 – Early Trials ESMO Asia 2023 - 1 week (New C3) disitamab vedotin Sensitive : C3 ESMO Asia 2023 - 1wk	disitamab vedotin Sensitive: C3 – Early Trials ESMO Asia 2023 - 1 week disitamab vedotin Sensitive : C3 ESMO Asia 2023 - 1 week - (New C3)
HER-2 amplification	Hormone Receptor Positive Breast Cancer	HER-2 amplification	Hormone Receptor Positive Breast Cancer	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 amplification	Hormone Receptor Positive Breast Cancer	HER-2 amplification	Hormone Receptor Positive Breast Cancer	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 amplification	Hormone Receptor Positive Breast Cancer	HER-2 amplification	Hormone Receptor Positive Breast Cancer	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 amplification	Hormone Receptor Positive Breast Cancer	HER-2 amplification	Hormone Receptor Positive Breast Cancer	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1
HER-2 amplification	Hormone Receptor Positive Breast Cancer	HER-2 amplification	Hormone Receptor Positive Breast Cancer	trastuzumab-pkrb Sensitive: A1 - Approval trastuzumab-pkrb Sensitive : A1	trastuzumab-pkrb Sensitive: A1 - Approval trastuzumab-pkrb Sensitive : A1
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	trastuzumab-pkrb Sensitive: A1 - Approval trastuzumab-pkrb Sensitive : A1	trastuzumab-pkrb Sensitive: A1 - Approval trastuzumab-pkrb Sensitive : A1
HER-2 amplification	Hormone Receptor Positive Breast Cancer	HER-2 amplification	Hormone Receptor Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
HER-2 amplification	Breast Cancer	HER-2 amplification	Breast Cancer	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval Zercepac (trastuzumab biosimilar) Sensitive : A1	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval Zercepac (trastuzumab biosimilar) Sensitive : A1
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
HER-2 amplification	Colorectal Cancer	HER-2 amplification	Colorectal Cancer	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2
HER-2 amplification	Colorectal Cancer	HER-2 amplification	Colorectal Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline fam-trastuzumab deruxtecan-nxki Sensitive : A2	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline fam-trastuzumab deruxtecan-nxki Sensitive : A2
HER-2 amplification	Colorectal Cancer	HER-2 amplification	Colorectal Cancer	trastuzumab + lapatinib Sensitive: A2 - Guideline trastuzumab + lapatinib Sensitive : A2	trastuzumab + lapatinib Sensitive: A2 - Guideline trastuzumab + lapatinib Sensitive : A2
HER-2 amplification	Rectal Cancer	HER-2 amplification	Rectal Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline fam-trastuzumab deruxtecan-nxki Sensitive : A2	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline fam-trastuzumab deruxtecan-nxki Sensitive : A2
HER-2 amplification	Gastric Cancer	HER-2 amplification	Gastric Cancer	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B
HER-2 amplification	Gastroesophageal Junction Adenocarcinoma	HER-2 amplification	Gastroesophageal Junction Adenocarcinoma	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B
HER-2 amplification	Gastric Cancer	HER-2 amplification	Gastric Cancer	lapatinib Sensitive: B - Late Trials lapatinib Sensitive : B	lapatinib Sensitive: B - Late Trials lapatinib Sensitive : B
HER-2 amplification	Gastroesophageal Cancer	HER-2 amplification	Gastroesophageal Cancer	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	pertuzumab + ado-trastuzumab emtansine Sensitive: B - Late Trials pertuzumab + ado-trastuzumab emtansine Sensitive : B	pertuzumab + ado-trastuzumab emtansine Sensitive: B - Late Trials pertuzumab + ado-trastuzumab emtansine Sensitive : B
HER-2 amplification	Breast Cancer	HER-2 amplification	Breast Cancer	neratinib Sensitive: C1 - Off-label neratinib Sensitive : C1	neratinib Sensitive: C1 - Off-label neratinib Sensitive : C1
HER-2 amplification	Breast Cancer	HER-2 amplification	Breast Cancer	lapatinib Sensitive: C2 – Inclusion Criteria lapatinib Sensitive : C2	lapatinib Sensitive: C2 – Inclusion Criteria lapatinib Sensitive : C2
HER-2 amplification	Breast Cancer	HER-2 amplification	Breast Cancer	tucatinib Sensitive: C2 – Inclusion Criteria tucatinib Sensitive : C2	tucatinib Sensitive: C2 – Inclusion Criteria tucatinib Sensitive : C2
HER-2 amplification	Non Small Cell Lung Cancer	HER-2 amplification	Non Small Cell Lung Cancer	rivoceranib + pyrotinib Sensitive: C2 – Inclusion Criteria rivoceranib + pyrotinib Sensitive : C2	rivoceranib + pyrotinib Sensitive: C2 – Inclusion Criteria rivoceranib + pyrotinib Sensitive : C2
HER-2 amplification	Gastroesophageal Junction Adenocarcinoma	HER-2 amplification	Gastroesophageal Junction Adenocarcinoma	pembrolizumab + trastuzumab Sensitive: C2 – Inclusion Criteria pembrolizumab + trastuzumab Sensitive : C2	pembrolizumab + trastuzumab Sensitive: C2 – Inclusion Criteria pembrolizumab + trastuzumab Sensitive : C2
HER-2 amplification	Gastric Cancer	HER-2 amplification	Gastric Cancer	pembrolizumab + trastuzumab Sensitive: C2 – Inclusion Criteria pembrolizumab + trastuzumab Sensitive : C2	pembrolizumab + trastuzumab Sensitive: C2 – Inclusion Criteria pembrolizumab + trastuzumab Sensitive : C2
HER-2 amplification	Solid Tumor	HER-2 amplification	Solid Tumor	KN046 + KN026 Sensitive: C2 – Inclusion Criteria KN046 + KN026 Sensitive : C2	KN046 + KN026 Sensitive: C2 – Inclusion Criteria KN046 + KN026 Sensitive : C2
HER-2 amplification	Non Small Cell Lung Cancer	HER-2 amplification	Non Small Cell Lung Cancer	afatinib Sensitive: C2 – Inclusion Criteria afatinib Sensitive : C2	afatinib Sensitive: C2 – Inclusion Criteria afatinib Sensitive : C2
HER-2 amplification	Solid Tumor	HER-2 amplification	Solid Tumor	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2